Media coverage about Mednax (NYSE:MD) has trended somewhat positive this week, Accern Sentiment reports. The research firm scores the sentiment of news coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Mednax earned a media sentiment score of 0.07 on Accern’s scale. Accern also assigned media stories about the company an impact score of 45.3261080008621 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Mednax (MD) traded down $0.21 during trading hours on Monday, reaching $51.43. 806,242 shares of the company’s stock were exchanged, compared to its average volume of 1,094,510. The company has a market cap of $4,836.36, a price-to-earnings ratio of 15.79, a P/E/G ratio of 1.66 and a beta of 0.40. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.37 and a current ratio of 1.37. Mednax has a 1-year low of $40.56 and a 1-year high of $72.13.
Mednax (NYSE:MD) last released its quarterly earnings data on Wednesday, November 1st. The company reported $0.87 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.87. The business had revenue of $868.95 million during the quarter, compared to analyst estimates of $864.78 million. Mednax had a net margin of 7.76% and a return on equity of 10.80%. Mednax’s revenue was up 4.9% compared to the same quarter last year. During the same period last year, the business earned $1.09 EPS. sell-side analysts anticipate that Mednax will post 3.1 EPS for the current fiscal year.
Several research firms have recently commented on MD. Citigroup dropped their target price on shares of Mednax from $52.00 to $47.00 and set a “neutral” rating for the company in a research report on Friday, November 3rd. Robert W. Baird raised their target price on shares of Mednax from $47.00 to $48.00 and gave the stock a “neutral” rating in a research report on Friday, November 3rd. Jefferies Group reaffirmed a “hold” rating and issued a $44.00 target price on shares of Mednax in a research report on Friday, November 3rd. KeyCorp set a $51.00 price target on shares of Mednax and gave the company a “buy” rating in a research report on Wednesday, November 1st. Finally, BMO Capital Markets assumed coverage on shares of Mednax in a research report on Monday, October 16th. They set a “market perform” rating and a $46.00 price target for the company. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and two have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $53.22.
In other news, insider John C. Pepia sold 3,000 shares of Mednax stock in a transaction that occurred on Tuesday, September 12th. The shares were sold at an average price of $42.85, for a total value of $128,550.00. Following the completion of the sale, the insider now directly owns 35,569 shares in the company, valued at $1,524,131.65. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Cesar L. Alvarez sold 10,668 shares of Mednax stock in a transaction that occurred on Friday, November 3rd. The stock was sold at an average price of $42.59, for a total transaction of $454,350.12. Following the completion of the sale, the director now owns 44,215 shares of the company’s stock, valued at $1,883,116.85. The disclosure for this sale can be found here. Insiders own 2.40% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This article was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this article on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright legislation. The original version of this article can be accessed at https://www.dispatchtribunal.com/2017/12/11/mednax-md-getting-somewhat-favorable-press-coverage-study-shows.html.
MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.
Receive News & Ratings for Mednax Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mednax Inc and related companies with MarketBeat.com's FREE daily email newsletter.